文献速递骨软组织肉瘤与黑色素瘤

黑色素瘤抗PD-1免疫治疗中迟发性免疫相关不良事件

Delayed immune-related adverse events with anti-PD-1-based immunotherapy in melanoma.
PubMed 文献 · Ann Oncol · 2021-03-30

研究描述了黑色素瘤患者接受抗PD-1为基础免疫治疗后迟发(>12个月)免疫相关不良事件(irAE)的发生率、特征与管理。在可评估的999例中,迟发irAE发生率为5.3%(95%CI 4.0-6.9),中位起病时间16个月,常见为结肠炎、皮疹和肺炎,39%为≥3级,两例死亡。

要点

  • 迟发irAE发生率约5.3%,中位起病16个月,多发生于仍在抗PD-1治疗者。
  • 迟发irAE常与既往早期irAE累及器官不同,且39%为≥3级,需警惕。
  • 决定应答患者治疗时长时应考虑迟发irAE风险,停药后仍需随访。

核心结论

  • 迟发irAE发生于少数但相关患者,可高分级甚至致死,多发生于仍在抗PD-1治疗者。

研究设计与样本

  • 多中心(20中心)观察性研究,分析接受抗PD-1为基础治疗的黑色素瘤患者中迟发irAE的发生率、特征与管理。

主要发现

  • 最常见迟发irAE为结肠炎、皮疹和肺炎,所有irAE中55次(39%)为≥3级。
  • 80例(68%)需激素,27例(23%)需额外免疫抑制剂;2例irAE相关死亡(脑炎和多器官irAE)。
  • 69例(58%)曾发生早期irAE(<12个月),其中59例(86%)迟发irAE累及不同器官。

临床怎么用

  • 对长期应答患者决定抗PD-1治疗时长时,应权衡迟发irAE风险;停药后仍需监测迟发irAE。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Immune-related adverse events (irAEs) typically occur within 4 months of starting anti-programmed cell death protein 1 (PD-1)-based therapy [anti-PD-1 ± anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA4)], but delayed irAEs (onset >12 months after commencement) can also occur. This study describes the incidence, nature and management of delayed irAEs in patients receiving anti-PD-1-based immunotherapy. PATIENTS AND METHODS: Patients with delayed irAEs from 20 centres were studied. The incidence of delayed irAEs was estimated as a proportion of melanoma patients treated with anti-PD-1-based therapy and surviving >1 year. Onset, clinical features, management and outcomes of irAEs were examined. RESULTS: One hundred and eighteen patients developed a total of 140 delayed irAEs (20 after initial combination with anti-CTLA4), with an estimated incidence of 5.3% (95% confidence interval 4.0-6.9, 53/999 patients at sites with available data). The median onset of delayed irAE was 16 months (range 12-53 months). Eighty-seven patients (74%) were on anti-PD-1 at irAE onset, 15 patients (12%) were <3 months from the last dose and 16 patients (14%) were >3 months from the last dose of anti-PD-1. The most common delayed irAEs were colitis, rash and pneumonitis; 55 of all irAEs (39%) were ≥grade 3. Steroids were required in 80 patients (68%), as well as an additional immunosuppressive agent in 27 patients (23%). There were two irAE-related deaths: encephalitis with onset during anti-PD-1 and a multiple-organ irAE with onset 11 months after ceasing anti-PD-1. Early irAEs (<12 months) had also occurred in 69 patients (58%), affecting a different organ from the delayed irAE in 59 patients (86%). CONCLUSIONS: Delayed irAEs occur in a small but relevant subset of patients. Delayed irAEs are often different from previous irAEs, may be high grade and can lead to death. They mostly occur in patients still receiving anti-PD-1. The risk of delayed irAE should be considered when deciding the duration of treatment in responding patients. However, patients who stop treatment may also rarely develop delayed irAE.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Owen CN, Bai X, Quah T, et al. Delayed immune-related adverse events with anti-PD-1-based immunotherapy in melanoma. Ann Oncol. 2021. PMID: 33798657. doi:10.1016/j.annonc.2021.03.204

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。